Invega Hafyera is owned by Janssen Pharms.
Invega Hafyera contains Paliperidone Palmitate.
Invega Hafyera has a total of 3 drug patents out of which 0 drug patents have expired.
Invega Hafyera was authorised for market use on 18 May, 2015.
Invega Hafyera is available in suspension, extended release;intramuscular dosage forms.
Invega Hafyera can be used as reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose, reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago, treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose.
The generics of Invega Hafyera are possible to be released after 07 May, 2041.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(13 years from now) | |
US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) | |
US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
4
United States
3
Japan
3
Australia
2
Morocco
2
Canada
2
European Union
1
Portugal
1
Moldova, Republic of
1
Spain
1
Brazil
1
Croatia
1
New Zealand
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Lithuania
1
Hungary
1
Slovenia
1
Ukraine
1
Poland
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic